Effects of treatment with etizolam 0.5 mg BID on cognitive performance: A 3-week, multicenter, randomized, double-blind, placebo-controlled, two-treatment, three-period, noninferiority crossover study in patients with anxiety disorder

Clinical Therapeutics

Volumn 31, Issue 12, 2009, Pages 2851-2859

  De Candia, Maria Pia ^a   Di Sciascio, Guido ^a   Durbano, Federico ^b   Mencacci, Claudio ^b   Rubiera, Marta ^c   Aguglia, Eugenio ^c   Garavini, Alessandra ^d   Bersani, Giuseppe ^d   Di Sotto, Antonella ^e   Placidi, Gianfranco ^e   Cesana, Bruno M ^f  

^a UNIVERSITY OF BARI   (Italy)

^b FATEBENEFRATELLI HOSPITAL   (Italy)

^c UNIVERSITY OF TRIESTE   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e UNIVERSITY OF FLORENCE   (Italy)

^f UNIVERSITY OF BRESCIA   (Italy)

Author keywords

anxiety; cognitive performance; crossover design; etizolam

Indexed keywords

ETIZOLAM; PLACEBO;

ADULT; ANXIETY DISORDER; ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; FEMALE; HAMILTON ANXIETY SCALE; HEART RATE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUROPSYCHOLOGICAL TEST; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; STATE TRAIT ANXIETY INVENTORY; SYSTOLIC BLOOD PRESSURE; WEAKNESS; WECHSLER INTELLIGENCE SCALE; WEIGHT GAIN;

ADMINISTRATION, ORAL; ADULT; ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; COGNITION; CROSS-OVER STUDIES; DIAZEPAM; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTELLIGENCE TESTS; ITALY; MALE; MIDDLE AGED; PLACEBO EFFECT; PSYCHOMETRICS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 74549134193     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.12.010     Document Type: Article

References (29)

1. Denver R.J. Structural and functional evolution of vertebrate neuroendocrine stress systems. Ann N Y Acad Sci. 1163 (2009) 1-16
2. Bersani G. Le Benzodiazepine Nella Pratica Medica e Psichiatrica (2001), Giovanni Fioriti Editore, Rome, Italy
3. Tiemens B.G., Ormel J., and Simon G.E. Occurrence, recognition, and outcome of psychological disorders in primary care. Am J Psychiatry. 153 (1996) 636-644
4. Bijl R.V., Ravelli A., and van Zessen G. Prevalence of psychiatric disorder in the general population: Results of The Netherlands Mental Health Survey and Incidence Study (NEMESIS). Soc Psychiatry Psychiatr Epidemiol. 33 (1998) 587-595
5. Kessler R.C., Berglund P., Demler O., et al. Lifetime prevalence and ageof-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication [published correction appears in Arch Gen Psychiatry. 2005;62:7658]. Arch Gen Psychiatry 62 (2005) 593-602
6. Davidson J.R. First-line pharmacotherapy approaches for generalized anxiety disorder. J Clin Psychiatry. 70 Suppl 2 (2009) 25-31
7. Longo L.P., and Johnson B. Addiction: Part I, Benzodiazepines-side effects, abuse risk and alternatives. Am Fam Physician. 61 (2000) 2121-2128
8. Licata S.C., and Rowlett J.K. Abuse and dependence liability of benzodiazepinetype drugs: GABA(A) receptor modulation and beyond. Pharmacol Biochem Behav. 90 (2008) 74-89
9. Neutel C.I. The epidemiology of long-term benzodiazepine use. Int Rev Psychiatry. 17 (2005) 189-197
10. Lydiard R.B. An overview of generalized anxiety disorder: Disease stateappropriate therapy. Clin Ther. 22 Suppl A (2000) A3-A19
11. discussion. Lydiard R.B. An overview of generalized anxiety disorder: Disease stateappropriate therapy. Clin Ther. 22 Suppl A (2000) A20-A24
12. Sanna E., Pau D., Tuveri F., Massa F., et al. Molecular and neurochemical evaluation of the effects of etizolam on GABAA receptors under normal and stress conditions. Arzneimittelforschung. 49 (1999) 88-95
13. Biggio G., Sanna E., and Serra M. Etizolam, un ansiolitico con ridotta capacità di indurre tolleranza e sedazione. Basi molecolari. Edit Symposia Psichiatrica, Speciale Biologia Molecolare (2004), Editeam, Ferrara, Italy
14. Sanna E., Busonero F., Talani G., et al. Low tolerance and dependence liabilities of etizolam: Molecular, functional, and pharmacological correlates. Eur J Pharmacol 519 (2005) 31-42
15. Information on etizolam at the Torrinomedica Institute. http://www.torrinomedica.it/studio/generaframe.asp?variabile=http://www.torrinomedica.it/farmaci/schedetecniche/PASADEN.asp Accessed November 26, 2009
16. Bellantuono C., and Balestrieri M. Gli Psicofarmaci (1997), Pensiero Scientifico Editore, Rome, Italy
17. D'Agostino Sr. R.B., Massaro J.M., and Sullivan L.M. Non-inferiority trials: Design concepts and issues-the encounters of academic consultants in statistics. StatMed. 22 (2003) 169-186
18. Snapinn S.M. Noninferiority trials. Curr Control Trials Cardiovasc Med. 1 (2000) 19-21
19. Piaggio G., Elbourne D.R., Altman D.G., et al., CONSORT Group. Reporting of noninferiority and equivalence randomized trials: An extension of the CONSORT statement [published correction appears in JAMA. 2006;296:1842]. JAMA 295 (2006) 1152-1160
20. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. 4th ed. (1994), American Psychiatric Association, Washington, DC
21. Bruss G.S., Gruenberg A.M., Goldstein R.D., and Barber J.P. Hamilton Anxiety Rating Scale Interview guide: Joint interview and test-retest methods for interrater reliability. Psychiatry Res. 53 (1994) 191-202
22. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Table of contents. http://ichgcp.net/ Accessed September 18, 2009
23. Wilde N.J., Strauss E., and Tulsky D.S. Memory span on the Wechsler scales. J Clin Exp Neuropsychol 26 (2004) 539-549
24. Wechsler D. WMS-R: Wechsler Memory Scale-Revised Manual (1987), The Psychological Corporation, Harcourt Brace Jovanovich, San Antonio, Tex
25. Orsini A., Grossi D., Capitani E., et al. Verbal and spatial immediate memory span: Normative data from 1355 adults and 1112 children. Ital J Neurol Sci. 8 (1987) 539-548
26. Spielberger C.D., Gorsuch R.L., and Lushene R.E. Manual for the State-Trait Anxiety Inventory (1970), Consulting Psychologists Press, Palo Alto, Calif
27. Jones B., and Kenward M.G. Design and Analysis of Cross-Over Trials (1989), Chapman and Hall, New York, NY
28. European Medicines Agency. ICH E9, Statistical Principles for Clinical Trials. http://www.emea.europa.eu/pdfs/human/ich/036396en.pdf Accessed January 30, 2009
29. Blashki G., Judd F., Piterman L., and Fumagalli E. Psichiatria e medicina generale (2007), McGraw-Hill, Milan, Italy